Close Menu

Novartis

The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant to treat certain PIK3CA-mutated breast cancers.

Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations.

A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.

Two studies showed that the addition of abemaciclib or ribociclib to fulvestrant improved overall survival in HR-positive, HER2-negative breast cancer patients.

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

While the oncology field moves toward NGS panel testing, the drugmaker has launched a program subsidizing single-gene testing for advanced melanoma patients.

Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.

Results from a Phase III trial presented at ASCO suggest a significant overall survival increase by adding ribociclib to endocrine therapy in HR-positive, HER2-negative breast cancer.

Novartis' alpelisib is the first PI3K inhibitor approved for advanced or metastatic breast cancer patients who harbor PIK3CA mutations.

The firm hopes for a decision from the FDA later this year for its breast cancer drug candidate alpelisib, following results from a late-stage trial.

Pages